EMA Authorised: Oprymea (pramipexole dihydrochloride monohydrate) — Krka, d.d., Novo mesto

View source ↗

Summary

EMA has authorised Oprymea (pramipexole dihydrochloride monohydrate) for the treatment of Parkinson's disease, under the marketing authorisation holder Krka, d.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Oprymea (pramipexole dihydrochloride monohydrate)

Snippet

Status: Authorised. Therapeutic area: Parkinson Disease. MAH: Krka, d.d., Novo mesto. Decision date: 20/08/2024